Document Classification

Section Type: RESULTS

Text: Selegiline hydrochloride increased trial end point (week 8) 7-day point prevalence smoking cessation rates (selegiline hydrochloride, 9/20 [45. 0 %] ; placebo, 3/20 [15. 0 %], odds ratio = 4. 64, 95 % CI, 1. 02-21. 00, p <. 05), and smoking cessation rates during the last 4 weeks of the trial (selegiline hydrochloride, 6/20 [30. 0 %] ; placebo, 1/20 [5. 0 %], odds ratio = 8. 14, 95 % CI, 0. 88-75. 48, p =. 07) in comparison with placebo.